Compare Nike Inc (NKE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nike Inc trades at $40.83 (market cap $60.10B), while State Street SPDR S&P Biotech ETF trades at $158.61. The key difference: Nike Inc pays a 4.05% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nike Inc nearer its low. Which is the better fit depends on your goals.
| NKE | XBI | |
|---|---|---|
Market Cap | $60.10B | — |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $79.17 | $164.28 |
52-Week Low | $40.51 | $88.79 |
Enterprise Value | $62.10B | — |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $41.32, down 1.88% on the day, reflecting ongoing investor caution amid revenue declines and margin pressures. Recent earnings beats have not offset concerns over sales weakness in key markets like China. Technical indicators are bearish, with the stock testing support near $41. The company maintains strong brand equity but faces execution risks in its turnaround strategy.
The outlook hinges on Nike's ability to stabilize revenue and improve margins through its 'Win Now' initiatives. Near-term catalysts include the Q4 2026 earnings report on June 30, 2026. Risks include persistent demand softness and competitive pressures, while the consensus price target of $50.45 suggests 22% upside if execution improves.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
